Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Vaccines made from mutated ras peptides may make the body build an immune response
to and kill tumor cells.
PURPOSE: Phase I trial to study the effectiveness of a vaccine containing mutated ras
peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung
cancer.